Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
82 results about "HIV Integrase Inhibitors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Integrase inhibitors are a type of antiretroviral treatment (ART), which has advanced a long way in a short time. Because of these advances, HIV is now a manageable disease for most people.
Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
ActiveUS7211572B2Effective anti-HIV agentStrong inhibitory activityBiocideOrganic chemistryAnti-HIV AgentSide effect
Owner:JAPAN TOBACCO INC
HIV integrase inhibitors
The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
Owner:BRISTOL MYERS SQUIBB CO
HIV integrase inhibitors: cyclic pyrimidinone compounds
The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses intermediates useful for making the pyrimidone compounds. Additionally, pharmaceutical compositions and methods for treating those infected with HIV are encompassed
Owner:BRISTOL MYERS SQUIBB CO
HIV integrase inhibitors
The present invention relates to a series of pyrimidine compounds of Formula I which inhibit HIV integrase and to pharmaceutical compositions and methods of treatment for AIDS or ARC using these compounds
Owner:BRISTOL MYERS SQUIBB CO
HIV integrase inhibitors
ActiveUS7135467B2Inhibit functioningEffective treatmentBiocideOrganic chemistryMedicineHIV Integrase Inhibitors
Owner:BRISTOL MYERS SQUIBB CO
Bicyclic heterocycles as HIV integrase inhibitors
The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV
Owner:BRISTOL MYERS SQUIBB CO
Bicyclic heterocycles as HIV integrase inhibitors
The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV
Owner:BRISTOL MYERS SQUIBB CO
Bicyclic heterocycles as HIV integrase inhibitors
The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV
Owner:BRISTOL MYERS SQUIBB CO
HIV integrase inhibitors
The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
Owner:BRISTOL MYERS SQUIBB CO
HIV integrase inhibitors
The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
Owner:BRISTOL MYERS SQUIBB CO
HIV Integrase Inhibitors
The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
Owner:BRISTOL MYERS SQUIBB CO
4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
ActiveUS20050239819A1Promote absorptionIncreased riskBiocideOrganic chemistrySide effectReverse transcriptase
An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I]wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.
Owner:JAPAN TOBACCO INC
HIV Integrase Inhibitors
The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
Owner:BRISTOL MYERS SQUIBB CO
Bicyclic heterocycles as HIV integrase inhibitors
The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
Owner:BRISTOL MYERS SQUIBB CO
Bicyclic heterocycles as HIV-integrase inhibitors
The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
Owner:BRISTOL MYERS SQUIBB CO
Process for preparing hexahydropyrimido[1,2-a]azepine-2-carboxylates and related compounds
InactiveUS20070142635A1High yieldLow costAntiviralsPhosphorus organic compoundsCarboxylic saltHIV Integrase Inhibitors
Processes for preparing 10-amino-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepine-2-carboxylates and related compounds are disclosed. The preparation of carboxamide derivatives from these carboxylates is also disclosed. The carboxamides are HIV integrase inhibitors and are useful for treating HIV infection and AIDS.
![Process for preparing hexahydropyrimido[1,2-a]azepine-2-carboxylates and related compounds](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/327ca0d5-2463-4ec2-9cc0-ebfc3042dd52/US20070142635A1-20070621-C00001.png "Process for preparing hexahydropyrimido[1,2-a]azepine-2-carboxylates and related compounds")
![Process for preparing hexahydropyrimido[1,2-a]azepine-2-carboxylates and related compounds](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/327ca0d5-2463-4ec2-9cc0-ebfc3042dd52/US20070142635A1-20070621-C00002.png "Process for preparing hexahydropyrimido[1,2-a]azepine-2-carboxylates and related compounds")
![Process for preparing hexahydropyrimido[1,2-a]azepine-2-carboxylates and related compounds](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/327ca0d5-2463-4ec2-9cc0-ebfc3042dd52/US20070142635A1-20070621-C00003.png "Process for preparing hexahydropyrimido[1,2-a]azepine-2-carboxylates and related compounds")
Owner:ASKIN DAVID +5
Phosphonate analogs of HIV integrase inhibitor compounds
InactiveUS20060116356A1Increasing cellular accumulation and retentionIncrease valueBiocidePhosphorous compound active ingredientsIntegrasesMedicinal chemistry
Novel HIV integrase inhibitor compounds having at least one phosphonate group, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.
Owner:GILEAD SCI INC
6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor
InactiveUS20080207618A1Strong inhibitory activityEffective anti-HIV agentsBiocideOrganic chemistryAnti-HIV AgentSide effect
The present invention relates to a compound represented by the following formula [I]wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical composition, an anti-HIV agent and an HIV integrase inhibitor containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an anti-HIV agent, or as an agent for the prophylaxis or treatment of AIDS. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Because it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.
Owner:JAPAN TOBACCO INC
Crystalline forms of an HIV integrase inhibitor
InactiveUS20080280945A1Improves moisture stabilityImprove thermal stabilityBiocideOrganic chemistryMedicineHIV Integrase Inhibitors
Crystalline forms of a hexahydro-diazocinonaphthyridine trione compound are disclosed. The compound and its crystalline forms thereof are HIV integrase inhibitors useful for the prophylaxis or treatment of HIV infection or for the prophylaxis, treatment or delay in the onset or progression of AIDS.
Owner:MERCK SHARP & DOHME CORP
HIV integrase inhibitors
The present invention describes novel compounds of Formula I which inhibit HIV integrase. The invention also describes compositions and treatments of AIDS or ARC by using these compounds
Owner:BRISTOL MYERS SQUIBB CO
Bicyclic heterocycles as HIV integrase inhibitors
The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
Owner:BRISTOL MYERS SQUIBB CO
HIV integrase inhibitors
The present invention describes novel compounds of Formula I which inhibit HIV integrase. The invention also describes compositions and treatments of AIDS or ARC by using these compounds.
Owner:BRISTOL MYERS SQUIBB CO
HIV integrase inhibitors
ActiveUS20040204498A1Broaden their knowledgeReduce riskBiocideOrganic chemistryHIV Integrase InhibitorsIntegrase inhibitor
Owner:BRISTOL MYERS SQUIBB CO
HIV integrase inhibitors: cyclic pyrimidinone compounds
The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses intermediates useful for making the pyrimidone compounds. Additionally, pharmaceutical compositions and methods for treating those infected with HIV are encompassed.
Owner:BRISTOL MYERS SQUIBB CO
HIV integrase inhibitors
ActiveUS20040229892A1Suppression of viral loadRestoration and preservation of immunologic functionBiocideOrganic chemistryIntegrasesHIV Integrase Inhibitors
The present invention relates to a series of pyrimidine compounds of Formula I which inhibit HIV integrase and to pharmaceutical compositions and methods of treatment for AIDS or ARC using these compounds.
Owner:BRISTOL MYERS SQUIBB CO
Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds
InactiveUS20080076738A1Increasing cellular accumulation and retentionIncrease valueBiocidePhosphorous compound active ingredientsIntegrasesMedicinal chemistry
Novel HIV integrase inhibitor compounds having at least one phosphonate group, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.
Owner:GILEAD SCI INC
HIV integrase inhibitors
The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
Owner:BRISTOL MYERS SQUIBB CO
4-oxoquinoline compounds and utilization thereof as HIV integrase inhibitors
ActiveCN1692101ALittle side effectsHighly specific inhibitory activityOrganic chemistryAntiviralsSide effectReverse transcriptase
An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula, wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.
Owner:JAPAN TOBACCO INC
HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use
Beta-carboline hydroxamic acid compounds represented by formula (I) are described. The beta-carboline hydroxamic acid compounds and compositions containing those compounds may be used to inhibit or modulate the activity of HIV integrase enzyme and to treat HIV integrase-mediated diseases and conditions.
Owner:AGOURON PHARMA INC
HIV integrase inhibitors
The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
Owner:BRISTOL MYERS SQUIBB CO
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com